亜宝薬業、2026年中間決算で親会社株主に帰属する純利益1.78億元、前年同期比1.83％増

Net profit attributable to parent increased 1.83% year-on-year, with gross margin rising for three consecutive quarters and diluted EPS achieving five consecutive years of growth.